ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 143.7 EUR | -0.26% |
|
+0.81% | +17.36% |
| 07-15 | Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast... |  |
| 07-15 | AstraZeneca: acquisition of Amolyt Pharma finalized | CF |
| Sales 2024 * | 51.62B 47.34B 70.57B | Sales 2025 * | 55.49B 50.89B 75.86B | Capitalization | 244B 223B 333B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.73B 8.01B 11.94B | Net income 2025 * | 10.46B 9.6B 14.31B | EV / Sales 2024 * | 5.13 x |
| Net Debt 2024 * | 20.99B 19.25B 28.7B | Net Debt 2025 * | 14.52B 13.32B 19.85B | EV / Sales 2025 * | 4.65 x |
| P/E ratio 2024 * |
27.9
x | P/E ratio 2025 * |
23.2
x | Employees | 89,900 |
| Yield 2024 * |
1.96% | Yield 2025 * |
2.07% | Free-Float | 96.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
| 1 day | -0.23% | ||
| 1 week | +0.81% | ||
| Current month | -2.49% | ||
| 1 month | -3.38% | ||
| 3 months | +11.81% | ||
| 6 months | +16.31% | ||
| Current year | +17.36% |
1 week
141.60
146.45
1 month
141.45150.00
Current year
112.45150.00
1 year
112.45150.00
3 years
94.00150.00
5 years
64.57150.00
10 years
47.74150.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 66 | 17-09-30 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Director/Board Member | 68 | 99-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 143 | -0.73% | 20 |
| 24-07-15 | 144 | -1.64% | 586 |
| 24-07-12 | 146.4 | +0.45% | 450 |
| 24-07-11 | 145.8 | +1.82% | 90 |
| 24-07-10 | 143.2 | +0.95% | 2,085 |
Delayed Quote Deutsche Boerse AG, July 16, 2024 at 03:12 am
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
157.2
USD
Average target price
177.6
USD
Spread / Average Target
+13.00%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.05% | 856B | |
| +39.54% | 631B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +5.24% | 234B | |
| +16.27% | 226B | |
| +14.63% | 177B | |
| +1.08% | 165B |
- Stock Market
- Equities
- AZN Stock
- ZEG Stock
